Exhibiting at VIV Asia 2025

Guangdong Wens Dahuanong Biotechnology Co., Ltd., based in Yunfu, China, is a major biotechnology company under the Wens Group, one of China's largest agricultural conglomerates. Specializing in veterinary pharmaceuticals and animal health products, the company plays a critical role in supporting China’s and Asia’s intensive livestock farming sectors through the development and supply of vaccines, veterinary drugs, and nutritional feed additives.

Core Business and Product Portfolio

Wens Dahuanong focuses on research, development, manufacturing, and commercialization of a wide array of animal health products. Their core offerings include:

• Veterinary Vaccines

  • Inactivated Vaccines: Used to protect poultry, swine, and ruminants against common viral and bacterial pathogens.
  • Live Attenuated Vaccines: Engineered for long-lasting immune responses, especially against viral infections such as Newcastle disease and avian influenza.

• Veterinary Drugs

  • Antibiotics: Used for treatment and prevention of bacterial diseases in farm animals.
  • Antiparasitics: Effective against internal and external parasites affecting poultry, pigs, and cattle.

• Feed Additives

  • Nutritional Supplements: Enhance animal growth, immunity, and overall productivity.
  • Growth Promoters: Improve feed conversion ratios and growth efficiency, especially in pig and poultry production.

These products are formulated to support disease prevention, treatment, and optimal growth performance in modern intensive livestock operations.

Technical Strength and Research Infrastructure

As part of the Wens Group’s vertically integrated operations, Dahuanong has access to high-level scientific infrastructure and an extensive animal farming base for product trials. Key technical strengths include:

• National-class enterprise technology center
• Post-doctoral research workstations
• Collaborations with top-tier veterinary institutions including South China Agricultural University

The company has also been involved in national research projects under China’s “863” and “973” programs for agricultural biotechnology.

Market Presence and Export Records

While primarily serving the domestic Chinese market, Wens Dahuanong has a growing international presence:

• Data from Volza and ImportYeti shows more than 200 international shipments in the past four years.
• Primary export destinations include Southeast Asia (Vietnam, Philippines, Thailand), Africa, and select Middle Eastern countries.
• Frequently exported products include avian vaccines, swine vaccines, and vitamin-enriched feed additives.

The company’s international business is supported by product registration approvals in multiple countries and strategic partnerships with local distributors.

Financial Strength and Parent Company Backing

Wens Dahuanong benefits from the strong financial and operational backing of Wens Foodstuff Group Co., Ltd., a Fortune China 500 company. As of 2022:

• Wens Group revenue: Over CNY 83 billion (~USD 12 billion)
• Dahuanong’s estimated annual sales: Approx. CNY 1.5 billion (~USD 210 million), according to industry publications
• Continuous reinvestment into R&D and facility upgrades from Wens Group corporate resources

This makes Dahuanong one of the largest veterinary biotech firms in China by production volume and R&D capacity.

Client Segments and Target Markets

The company supplies to:

• Commercial pig and poultry farms
• Veterinary service providers
• Feed integrators
• Government animal health departments

With its vertically integrated model, many of Dahuanong’s products are deployed across the Wens Group’s extensive internal farming network before commercialization, ensuring proven efficacy.

Manufacturing Infrastructure and Capacity

The company operates multiple GMP-certified production lines covering:

• Viral and bacterial vaccine production (biosafety level P2)
• Fermentation and chemical synthesis of veterinary drugs
• Feed additive blending and packaging

Dahuanong’s vaccine facilities can produce over 10 billion doses annually, making it one of the highest-capacity animal vaccine manufacturers in China.

Certifications and Compliance

Wens Dahuanong adheres to both domestic and international quality standards, including:

• GMP certification for veterinary pharmaceuticals (China MOA)
• ISO 9001 and ISO 14001
• Product registrations with veterinary authorities in Southeast Asia, the Middle East, and Africa

These certifications allow the company to meet stringent quality and safety regulations in both domestic and export markets.

Industry Reputation and Achievements

Although specific testimonials are limited in public records, Dahuanong is consistently featured in China’s national rankings for veterinary biological product manufacturers. Key achievements include:

• National High-Tech Enterprise designation
• Supplier for national disease control programs in poultry and swine sectors
• Zero product recall incidents reported in past 5 years
• Winner of provincial awards for innovation in veterinary immunology

Its active participation in global livestock expos and forums underlines its intent to scale its brand in the international veterinary pharmaceutical landscape.

Guangdong Wens Dahuanong Biotechnology Co., Ltd. exemplifies the convergence of high-volume manufacturing and advanced veterinary biotechnology, backed by deep integration with one of the largest agribusiness ecosystems in Asia.